Sold $EXEL, bougth more $ACAD

The biotech industry has been in a two day correction after an amazing run the past few weeks.  Most traders believe this is good for overall fundamentals and companies with strong financials and upcoming catalysts should start to run back up. 

ACAD is one of the companies that saw their morning low hitting of $2.31 it recovered and closed at 2.53.  I was not able to buy close to the days low but was able to scoop additonal share at $2.45

Just a reminder, ACAD has a catalyst in late november, Phase 3 efficacy, tolerability, and safety data for Primavarserin in Parkinson's disease pychosis.

As for EXEL, it has traded very strange the last couple of days, not sure what is going on with this stock. but I'm staying out of it for now.